相关实验视频
Updated: Jan 6, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
上腺皮癌的基于多omics的分子分类预测了对免疫疗法和向治疗的反应
Xingwei Jin1, Xianjin Wang1, Zhiyuan Wang2
1Department of UrologyRuijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
确定了上皮层癌 (ACC) 的分子亚型,指导个性化治疗. 一种亚型 (MACCS1) 预后不佳,与HOXC11有关,HOXC11是潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 上皮层癌 (ACC) 具有侵略性,结果不佳,特别是在转移时.
- 目前的治疗方法对晚期的ACC缺乏有效性,原因是未定义的治疗点.
- 新的分子分类对于开发精确的治疗策略至关重要.
研究的目的:
- 整合多omics数据用于ACC的强大的分子亚型.
- 为了确定每个亚型的独特的生物学表型和药物敏感性.
- 发现ACC的新预后因素和治疗点.
主要方法:
- 转录组,表观遗传和基因组变异数据的整合.
- 应用10个聚类算法来识别分子亚型 (MACCS1和MACCS2).
- 药物敏感性分析,随机森林建模和功能测试 (HOXC11沉默).
主要成果:
- 确定了两个强大的ACC分子亚型,MACCS1 (增殖驱动) 和MACCS2 (免疫激活).
- MACCS2对免疫检查点抑制剂表现出敏感性;MACCS1对氨酸激酶抑制剂做出反应.
- HOXC11被确定为MACCS1的预后因素,高表达与瘤进展相关,并在沉默后减少扩散.
结论:
- 这项研究建立了ACC的分子分类 (MACCS),使得个性化治疗策略成为可能.
- MACCS2可能对免疫疗法有反应,而MACCS1可能从向治疗中受益.
- HOXC11被强调为ACC的MACCS1亚型的潜在治疗标.
更多相关视频
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
08:30Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
Published on: October 9, 2018
相关概念视频
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Treatment Resistant Cancers